Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical has announced that its subsidiary’s drug registration application for Raltitrexed for Injection has been accepted by the National Medical Products Administration. This new chemical drug is intended as a treatment for advanced colorectal cancer in patients unsuitable for certain combination chemotherapies. The company has invested approximately RMB2.96 million in the drug’s research and development.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.